Search clinical trials for: Long Acting Injectable Antipsychotic

Total 74069 results

University of Liverpool
Obafemi Awolowo University Teaching Hospital; Federal Medical Centre, Makurdi; Federal Neuropsychiatric Hospital, Yaba and other collaborators

Recruiting

Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum (LAMP)

Schizophrenia | Pregnancy | Mania | Psychosis | Breastfeeding | Antipsychotic Agents | Drug Exposure in Utero | Drug Exposure Via Breast Milk

Nigeria
Rovi Pharmaceuticals Laboratories

Recruiting

Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse (RESHAPE)

Schizophrenia

Germany
Centre for Addiction and Mental Health
Janssen Inc.

Recruiting

Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

Schizophrenia | Schizophrenia Relapse

Canada
Otsuka Canada Pharmaceutical Inc.
Lundbeck Canada Inc.

Recruiting

Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE) (INITIATE)

Schizophrenia | Schizo Affective Disorder | Bipolar I Disorder

Canada
Janssen-Cilag International NV

Completed

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (CASPAR)

Schizophrenia

Rwanda
University of California, Los Angeles
National Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLC

Completed

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

Schizophrenia

United States
University of California, Los Angeles
National Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLC

Completed

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

Schizophrenia (Recent-onset)

United States
Martha Sajatovic
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

Bipolar Disorder | Medication Adherence | Medication Non Adherence

United States
Rovi Pharmaceuticals Laboratories

Completed

Comparative Bioavailability of Risperidone.

Schizophrenia

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics (MAESTRO)

Schizophrenia | Antipsychotics | Long-Acting Injection | LAI | Aripiprazole

Korea, Republic of
Rovi Pharmaceuticals Laboratories

Completed

Comparative Bioavailability of Risperidone

Schizophrenia

United States
Vanguard Research Group
Otsuka America Pharmaceutical

Completed

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics (PRELAPSE)

Schizophrenia

United States
Azienda Socio Sanitaria Territoriale degli Spedali...

Unknown

A Study in Italy About Evidence Based Psychosocial/Rehabilitative Interventions in Patients With Early Schizophrenia Treated Continuously With Antipsychotics (ESCHILO)

Schizophrenia

Italy
University Hospitals Cleveland Medical Center

Completed

A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness (CAL-C)

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder | Medication Adherence | Medication Non-Adherence

United States
Northwestern University
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Europe Ltd
H. Lundbeck A/S

Unknown

Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia

Schizophrenia

Spain, Italy, France, Germany
Abdi İbrahim Otsuka

Completed

Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch (ARILAI)

Schizophrenia

Turkey
Otsuka Pharmaceutical Europe Ltd

Completed

Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain (PROSIGO)

Schizophrenia

Spain
Northwell Health
National Alliance for Research on Schizophrenia and Depression; The Zucker...

Terminated

Optimizing Response in Psychosis Study (ORP)

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Psychotic Disorder Not Otherwise Specified

United States
Vanderbilt University
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder? (Consta)

Bipolar Disorder

United States
Otsuka Pharmaceutical Europe Ltd

Completed

Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy (DOMINO)

Schizophrenia

Italy
New York State Psychiatric Institute
National Institute of Mental Health (NIMH); Duke University; University of North...

Completed

A Comparison of Long-acting Injectable Medications for Schizophrenia (ACLAIMS)

Schizophrenia | Schizoaffective Disorder

United States
Janssen-Cilag Ltd.

Completed

A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics (REALAI)

Schizophrenia

Mexico, Brazil
University of Pittsburgh
Janssen Pharmaceuticals

Completed

Risperdal Consta for Bipolar Disorder

Bipolar I Disorder

United States
University Hospitals Cleveland Medical Center
Case Western Reserve University

Completed

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L)

Patient Noncompliance

United States
Janssen-Cilag Farmaceutica Ltda.

Completed

Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate

Schizophrenia

Colombia, Mexico, Brazil
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Schizophrenia

United States, Ukraine, Germany, Spain, India, Russian Federation, Czech Republic, Austria, Hungary, Lithuania, Bulgaria, Estonia, Poland, France
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

Schizophrenia

United States, Ukraine, Taiwan, Malaysia, Romania, Russian Federation, Serbia, Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Psychotic Disorders | Schizophrenia

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

Bipolar Disorder

China, Taiwan, Colombia, India, Malaysia, Russian Federation, South Africa, Greece, Peru, Germany, Mexico, Lebanon, Indonesia, Philippines, Jordan
Janssen-Cilag International NV

Completed

A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia

France, Poland, Germany, Spain, Slovenia, Bulgaria, Romania, Israel, Greece, Sweden, Turkey, Czech Republic, Hungary, Lithuania, Latvia, Portugal, Croatia, Slovakia, Austria, United Kingdom, Estonia, Ireland, Denmark, Saudi Arabia
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia

Schizophrenia | Schizoaffective Disorder

Korea, Republic of
Janssen Korea, Ltd., Korea

Completed

A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)

Mental Disorders | Schizophrenia | Tranquilizing Agents | Therapeutic Uses | Physiological Effects of Drugs | Psychotropic Drugs | Antipsychotic Agents
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder

Schizophrenia

Korea, Republic of
Janssen Scientific Affairs, LLC

Completed

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

Schizophrenia | Bipolar Disorder

United States
US Department of Veterans Affairs

Completed

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Janssen Pharmaceutica N.V., Belgium

Completed

Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

Schizophrenia

United Kingdom, Slovenia, Denmark, Finland, France, Greece, Israel, Norway, Sweden, Switzerland
Xian-Janssen Pharmaceutical Ltd.

Completed

A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia

Schizophrenia

China
Janssen-Cilag S.p.A.

Completed

Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Janssen-Cilag International NV

Completed

InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics

Schizophrenia

France, Germany, Spain, South Africa, Turkey, Greece, Czech Republic, Russian Federation
Janssen Pharmaceutica N.V., Belgium

Completed

A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis

Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Janssen, LP

Completed

A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.

Schizophrenia | Schizoaffective Disorder
Janssen, LP

Completed

A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.

Schizophrenia | Schizoaffective Disorder

Search clinical trials for: Long Acting Injectable Antipsychotic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations